TP53 and cancer: Since Nutlin-3 was originally developed as a non-genotoxic anti-cancer drug33 and is a compound that is most commonly used in anti-cancer studies58, 59, our findings draw attention to new potential effects of this anti-cancer drug via p53 activation.